Enveric Biosciences, Inc.
ENVB- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000890821
No open-market purchases or sales by Enveric Biosciences, Inc. insiders were filed in the last 90 days; 24 institutions reported holding it in 13F filings for Q2 2026, worth $736.8K in total; no superinvestor holds it.
Q2 2023 vs. Q1 2023
How the institutions holding Enveric Biosciences, Inc. changed between Q1 2023 and Q2 2023.
All holders in Q2 2023All holders in Q1 2023
| Measure | Q1 2023 | Q2 2023 | Change |
|---|---|---|---|
| Holders | 13 | 14 | +1 |
| Shares | 228.1K | 187.3K | −40.8K (−17.9%) |
| Value | $382.4K | $631.1K | +$248.7K (+65.0%) |
New holders (4)
Institutions that held Enveric Biosciences, Inc. at the end of Q2 2023 but not at the end of Q1 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Renaissance Technologies LLC | 17,170 | $58.0K | 0.00% |
| Citadel Advisors LLC | 13,933 | $47.0K | 0.00% |
| Acadian Asset Management LLC | 4,559 | $15.0K | 0.00% |
| National Bank of Canada | 70 | $232 | 0.00% |
Sold out (3)
Institutions that held Enveric Biosciences, Inc. at the end of Q1 2023 and filed for Q2 2023 without it.
| Institution | Shares, Q1 2023 | Value, Q1 2023 |
|---|---|---|
| Susquehanna International Group, LLP | 12,481 | $21.0K |
| Virtu Financial LLC | 10,683 | $18.0K |
| Advisor Group Holdings, Inc. | 150 | $249 |